# TIVO-3 (NCT02627963)

> A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)

No report yet. It can be ordered.

- Drugs tested: tivozanib
- Indication: relapsed/refractory advanced renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02627963
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: AVEO Pharmaceuticals, Inc.
- Conditions: Carcinoma, Renal Cell
- Interventions: Tivozanib hydrochloride; Sorafenib
- Enrollment: 350
- Primary outcome: Progression-free Survival (PFS)

## Indexed commentary on TIVO-3 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 37 posts on X
- 23 YouTube videos
- 21 podcast episodes
- 1 video on X

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=tivo-3-nct02627963

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02627963", "email": "<work email>"}; the inbox owner confirms by the emailed link.